Search

ZUMA-24: A PHASE 2, OPEN-LABEL STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN OUTPATIENT WITH CORTICOSTEROIDS B Introduction: b Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of adults with relapsed or refractory ( I R i / I R i ) large B-cell lymphoma (LBCL) after >=2 lines of systemic therapy and for I R i / I R i LBCL within 12 months of first-line chemoimmunotherapy. Key exclusion criteria include >1 prior line of therapy for LBCL, prior stem cell transplant, and prior anti-CD19 or CAR T-cell therapy. [Extracted from the article]

B Introduction: b Most patients (pts) with LBCL respond to axi-cel, but many will eventually experience disease progression (Jacobson et al. I JCO i . 2020). Monitoring of ctDNA from blood, a minimally invasive diagnostic tool, has been used to assess measurable residual disease (MRD) with prognostic value, including in pts with diffuse LBCL treated with axi-cel in the third line of therapy (3L; Frank et al. I JCO i . 2019). Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). [Extracted from the article]